Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced a conference call and webcast on March 25, 2021, at 4:30 p.m. ET. The call will cover a corporate update and the results for Q4 and the full year 2020. Interested participants can join by calling 877-407-0789 domestically or 201-689-8562 internationally, using Conference ID 13717079. The live webcast is accessible via their Investor Relations website.
Viridian focuses on developing treatments for serious diseases, notably VRDN-001, an anti-IGF-1R monoclonal antibody for thyroid eye disease.
Viridian Therapeutics (NASDAQ: VRDN), a biopharmaceutical company, announced that CEO Jonathan Violin will present at several upcoming investor conferences. Key events include the SVB Leerink 10th Annual Global Healthcare Conference on February 24, the Cowen 41st Annual Health Care Conference on March 3, and the Oppenheimer 31st Annual Healthcare Conference on March 16. Each presentation will be available for online viewing, with replays archived for 90 days. The company's lead program, VRDN-001, targets thyroid eye disease.
Viridian Therapeutics, formerly miRagen Therapeutics, has appointed Jonathan Violin, Ph.D., as President and CEO, succeeding Lee Rauch, who remains a strategic advisor. Barrett Katz, M.D., has joined as Chief Medical Officer. The company is developing VRDN-001 and VRDN-002 for thyroid eye disease, targeting a significant unmet medical need. Recent licensing from Xencor allows for the development of therapeutic antibodies. Viridian aims to file Investigational New Drug applications for both products in 2021.